Mitochondrial target of thiazolidinediones

Diabetes, Obesity and Metabolism

Volumn 16, Issue 11, 2014, Pages 1048-1054

  Colca, J R ^a   Mcdonald, W G ^a   Kletzien, R F ^a  

^a Metabolic Solutions Development Company   (United States)

Author keywords

Diabetes mellitus; Insulin resistance; Thiazolidinediones

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; INSULIN SENSITIZING AGENT; INSULIN;

AGING; DIABETES MELLITUS; HUMAN; HYPOTHESIS; METABOLIC DISORDER; MITOCHONDRION; NEOPLASM; NERVE DEGENERATION; NONHUMAN; PLEIOTROPY; REVIEW; ANIMAL; DISEASE MODEL; DROSOPHILA; DRUG DEVELOPMENT; DRUG EFFECTS; GENETICS; INSULIN RESISTANCE; KNOCKOUT MOUSE; METABOLIC DISEASES; METABOLISM; MOLECULARLY TARGETED THERAPY; MOUSE; SECRETION (PROCESS);

ANIMALS; DISEASE MODELS, ANIMAL; DROSOPHILA; DRUG DISCOVERY; HUMANS; INSULIN; INSULIN RESISTANCE; METABOLIC DISEASES; MICE; MICE, KNOCKOUT; MITOCHONDRIA; MOLECULAR TARGETED THERAPY; THIAZOLIDINEDIONES;

EID: 84907043799     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12308     Document Type: Review

References (52)

1. Fujita T, Sugiyama Y, Taketomi S et al. Reduction of insulin resistance in obese and/or diabetic animals by 5-[4-(1-methylcyclohexylmethoxy)benzyl]-thiazolidine-2, 4-dione (ADD-3878, U-63, 287, Ciglitazone), a new antidiabetic agent. Diabetes 1983; 32: 804-810.
2. Hofmann CA, Colca JR. New oral thiazolidinedione antidiabetic agents act as insulin sensitizers. Diabetes Care 1992; 15: 1075-1078.
3. Bailey CJ, Day C. Thiazolidinediones today. Br J Diabetes Vasc Dis 2011; 1: 7-13.
4. Owens DR. Thiazolidinediones: a pharmacological review. Clin Drug Invest 2002; 22: 485-505.
5. Giannini S, Serio M, Galli A. Pleiotropic effects of thiazolidinediones: taking a look beyond antidiabetic activity. J Endocrinol Invest 2004; 27: 982-991.
6. Henry RR, Erickson D, Ciaraldi TP. PPAR {gamma} agonists and the future for insulin sensitizers: a report of a debate and presentations on the subject at the 72nd Scientific Sessions of the American Diabetes Association, Philadelphia, 8-12 June, 2012. Br J Diabetes Vasc Dis 2012; 12: 206-210.
7. Erdmann E, Wilcox RG. Weighing up the cardiovascular benefits of thiazolidinedione therapy: the impact of increased risk of heart failure. Eur Heart J 2008; 29: 12-20.
8. Colca JR, Kletzien RF. What has prevented the expansion of insulin sensitizers? Expert Opin Investig Drugs 2006; 15: 205-210.
9. Colca JR. Insulin sensitizers may prevent metabolic inflammation. Biochem Pharmacol 2006; 72: 125-131.
10. Colca JR, Tanis SP, McDonald WG, Kletzien RK. Insulin sensitizers in 2013: new insights for the development of novel therapeutic agents to treat metabolic diseases. Expert Opin Investig Drugs 2013; 23: 1-7.
11. Feinstein DL, Spagnolo A, Akar C et al. Receptor independent actions of PPAR thiazolidinedione agonist: is mitochondrial function the key? Biochem Pharmacol 2005; 70: 177-188.
12. Szendroedi J, Schmid AI, Meyerspeer M et al. Impaired mitochondrial function and insulin resistance of skeletal muscle in mitochondrial diabetes. Diabetes Care 2009; 32: 677-679.
13. Simmons RA, Suponitsky-Kroyter I, Selak MA. Progressive accumulation of mitochondrial DNA mutations and decline in mitochondrial function lead to {beta}-cell failure. J Biol Chem 2005; 280: 28785-28791.
14. Kim J, Wei Y, Sowers JR. Role of mitochondrial dysfunction in insulin resistance. Circ Res 2008; 102: 401-414.
15. Brunmair B, Gras F, Neschen S et al. Direct thiazolidinedione action on isolated skeletal muscle fuell handling is independent of peroxisome proliferator-activated receptor-[gamma]-mediated changes in gene expression. Diabetes 2001; 50: 2309-2315.
16. Brunmair B, Staniek K, Gras F et al. Thiazolidinediones, like metformin, inhibit respiratory complex I: a common mechanism leading to their antidiabetic actions? Diabetes 2004; 53: 1052-1059.
17. Konrad D, Rudich A, Bilan PJ et al. Troglitazone causes acute mitochondrial membrane depolarisation and an AMPK-mediated increase in glucose phosphorylation in muscle cells. Diabetologia 2005; 48: 954-966.
18. LeBrasseur NK, Kelly M, Tsao T-S et al. Thiazolidinediones can rapidly activate AMP-activated protein kinase in mammalian tissues. Am J Physiol Endocrinol Metab 2006; 291: E175-181.
19. Lessard SJ, Chen Z-P, Watt MJ et al. Chronic rosiglitazone treatment restores AMPK{alpha}2 activity in insulin-resistant rat skeletal muscle. Am J Physiol Endocrinol Metab 2006; 290: E251-257.
20. Ye J-M, Dzamko N, Hoy AJ, Iglesias MA, Kemp B, Kraegen E. Rosiglitazone treatment enhances acute AMP-activated protein kinase-mediated muscle and adipose tissue glucose uptake in high-fat-fed rats. Diabetes 2006; 55: 2797-2804.
21. Fryer LGD, Parbu-Patel A, Carling D. The antidiabetic drugs rosiglitazone and metformin stimulate AMP-activated protein kinase through distinct signaling pathways. J Biol Chem 2002; 277: 25226-25232.
22. Seufert J, Lübben G, Dietrich K, Bates PC. A comparison of the effects of thiazolidinediones and metformin on metabolic control in patients with type 2 diabetes mellitus. Clin Ther 2004; 26: 805-818.
23. Colca JR, McDonald WG, Waldon DL et al. Identification of a novel mitochondrial protein ("mitoNEET") cross-linked specifically by a thiazolidinedione photoprobe. Am J Physiol 2004; 286: E252-260.
24. Wiley SE, Paddock ML, Abresch EC et al. The outer mitochondrial membrane protein mitoNEET contains a novel redox-active 2Fe-2S cluster. J Biol Chem 2007; 282: 23745-23749.
25. Kusminski CM, Holland WL, Sun K et al. MitoNEET-driven alterations in adipocyte mitochondrial activity reveal a crucial adaptive process that preserves insulin sensitivity in obesity. Nat Med 2012; 18: 1539-1549.
26. Colca JR, McDonald WG, Cavey GS et al. Identification of a mitochondrial target of thiazolidinedione insulin sensitizers (mTOT)-relationship to newly identified mitochondrial pyruvate carrier proteins. PLoS One 2013; 8: 1-10.
27. Bricker DK, Taylor EB, Schell JC et al. A mitochondrial pyruvate carrier required for pyruvate uptake in yeast, Drosophila, and humans. Science 2012; 337: 96-100.
28. Herzig S, Raemy E, Montessuit S et al. Identification and functional expression of the mitochondrial pyruvate carrier. Science 2012; 337: 93-96.
29. Divakaruni AS, Murphy AN. A mitochondrial mystery, solved. Science 2012; 337: 41-43.
30. Divakaruni AS, Wiley SE, Rogers GW et al. Thiazolidinediones are acute, specific inhibitors of the mitochondrial pyruvate carrier. Proc Natl Acad Sci U S A 2013; 110: 5422-5427.
31. Wu P, Inskeep K, Bowler-Kinley MM, Popov KM, Harris RA. Mechanism responsible for inactivataion of skeletal muscle pyruvate dehydrogenase complex in starvation and diabetes. Diabetes 1999; 48: 1593-1599.
32. Cadoudal T, Distel E, Durant S et al. Pyruvate dehydrogenase kinase 4 regulation by thiazolidinediones and implication in glyceroneogenesis in adipose tissue. Diabetes 2008; 57: 2272-2279.
33. Garcia-Ruiz I, Solis-Munoz P, Fernandez-Moreira D, Munoz-Yague T, Solis-Hurruzo JA. Piolgitazone leads to an inactivation and disassembly of complex I of the mitochondrial respiratory chain. BMC Biol 2013; 11: 88.
34. She P, Van Horn C, Reid T, Hutson SM, Cooney RN, Lynch CJ. Obesity-related elevations in plasma leucine are associated with alterations in enzymes involved in branched-chain amino acid metabolism. Am J Physiol Endocrinol Metab 2007; 293: E1552-1563.
35. Adeva MM, Calvino J, Souto G, Donapetry C. Insulin resistance and the metabolism of branched-chain amino acids in humans. Amino Acids 2012; 43: 171-181.
36. Newgard CB. Interplay between lipids and branched-chain amino acids in development of insulin resistance. Cell Metab 2012; 15: 606-614.
37. Um SH, D'Alessio D, Thomas G. Nutrient overload, insulin resistance, and ribosomal protein S6 kinase 1, S6K1. Cell Metab 2006; 3: 393-402.
38. Tremblay F, Sophie Brûlé S, Um SH et al. Identification of IRS-1 Ser-1101 as a target of S6K1 in nutrient- and obesity-induced insulin resistance. Proc Natl Acad Sci U S A 2007; 104: 14056-14061.
39. Guo S. Insulin signaling, resistance, and metabolic syndrome: insights from mouse models into disease mechanisms. J Endocrinol 2014; 220: T1-23.
40. Liu H, Remedi MS, Pappan KL et al. Glycogen synthase kinase-3 and mammalian target of rapamycin contribute to DNA synthesis, cell cycle progression, and proliferation in human islets. Diabetes 2009; 58: 663-672.
41. Rachdi L, Aiello V, Duvillie B, Scharfmann R. L-leucine alters pancreatic b-cell differentiation and function via the mTor pathways. Diabetes 2012; 61: 409-417.
42. Xiao F, Huang Z, Li H et al. Leucine deprivation increases hepatic insulin sensitivity via GCN2/mTOR/S6K1 and AMPK pathways. Diabetes 2011; 60: 746-756.
43. Laplante M, Sabatini DM. Regulation of mTOTC1 and its impact on gene expression at a glance. J Cell Sci 2013; 126: 1713-1719.
44. McCormick MA, S-y T, Kennedy BK. TOR and aging: a complex pathway for a complex process. Philos Trans R Soc B 2011; 366: 17-27.
45. Rohatgi N, Aly H, Marshall CA et al. Novel insulin sensitizer modulates nutrient sensitizing pathways and maintains β-cell phenotype in human islets. PLoS One 2013; 8: e62012.
46. Unger RH. Lipotoxicity in the pathogenesis of obesity-dependent NIDDM: genetic and clinical implications. Diabetes 1995; 44: 863-870.
47. Teranishi T, Ohara T, Maeda K et al. Effects of pioglitazone and metformin on intracellular lipid content in liver and skeletal muscle of individuals with type 2 diabetes mellitus. Metabolism 2007; 56: 1418-1424.
48. Itani SI, Ruderman NB, Schmieder F, Boden G. Lipid-induced insulin resistance in human muscle is associated with changes in diacylglycerol, protein kinase C, and I{kappa}B-{alpha}. Diabetes 2002; 51: 2005-2011.
49. Abdul-Ghani MA, Muller FL, Liu Y et al. Deleterious action of FA metabolites on ATP synthesis: possible link between lipotoxicity, mitochondrial dysfunction, and insulin resistance. Am J Physiol Endocrinol Metab 2008; 295: E678-685.
50. Chen Z, Vigueira PA, Chambers KT et al. Insulin resistance and metabolic derangements in obese mice are ameliorated by a novel peroxisome proliferator-activated receptor γ -sparing thiazolidinedione. J Biol Chem 2012; 287: 23537-23548.
51. DeFronzo RA, Tripathy D, Schwenke DC et al., for the ACT NOW Study. Prevention of diabetes with pioglitazone in ACT NOW: physiologic correlates. Diabetes 2013; 62: 3920-3926.
52. Colca JR, Feinstein DL. Altering mitochondrial dysfunction as an approach to treating Alzheimer's disease. Adv Pharmacol 2012; 64: 155-176.